price
AB
NASDAQ · ABCL
AbCellera Biologics Inc.
Healthcare · Biotechnology
$11.67
Up+$0.26 (+2.28%)
Updated Sep 17, 2026, 9:40 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.08B
- P/E ratio
- -7.37
- Dividend yield
- 0.00%
- 52-week range
- $3.22 – $12.58
- Volume
- 4.54M
- Avg. volume
- 4.11M
Price performance
ABCL price history
1M range · 20 trading sessions · Daily adjusted prices
ABCL closed at $11.67 after 20 trading sessions, down 2.83% for the selected period.
- Last close
- $11.67
- Period change
- -2.83%
- Period low
- $10.46
- Period high
- $12.50
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $11.44 | $11.73 | $11.175 | $11.67 | 4.54M |
| Sep 15, 2026 | $11.17 | $11.69 | $10.90 | $11.41 | 3.73M |
| Sep 14, 2026 | $10.66 | $11.305 | $10.66 | $11.17 | 4.45M |
| Sep 11, 2026 | $10.55 | $10.955 | $10.32 | $10.89 | 4.38M |
| Sep 10, 2026 | $10.79 | $11.07 | $10.42 | $10.46 | 4.94M |
| Sep 9, 2026 | $11.37 | $11.45 | $11.01 | $11.05 | 2.41M |
| Sep 8, 2026 | $11.29 | $11.64 | $11.10 | $11.44 | 2.56M |
| Sep 4, 2026 | $11.50 | $11.59 | $11.33 | $11.43 | 2.02M |
| Sep 3, 2026 | $11.58 | $11.82 | $11.26 | $11.57 | 3.29M |
| Sep 2, 2026 | $11.39 | $11.5699 | $10.80 | $11.36 | 3.73M |
| Sep 1, 2026 | $11.24 | $11.52 | $11.05 | $11.28 | 4.25M |
| Aug 31, 2026 | $11.10 | $11.575 | $10.83 | $11.48 | 4.96M |
| Aug 28, 2026 | $12.305 | $12.35 | $11.26 | $11.35 | 5.86M |
| Aug 27, 2026 | $12.25 | $12.5799 | $12.085 | $12.40 | 4.27M |
| Aug 26, 2026 | $12.22 | $12.36 | $12.05 | $12.24 | 5.04M |
| Aug 25, 2026 | $11.00 | $12.50 | $10.99 | $12.50 | 10.7M |
| Aug 24, 2026 | $10.97 | $11.01 | $10.44 | $10.61 | 6.59M |
| Aug 21, 2026 | $11.57 | $11.7999 | $11.14 | $11.32 | 4.55M |
| Aug 20, 2026 | $11.815 | $12.08 | $11.40 | $11.57 | 6.18M |
| Aug 19, 2026 | $11.50 | $12.15 | $11.47 | $12.01 | 10.81M |
Latest ABCL news
The latest Smart Investors Daily articles mentioning ABCL.
Stock researchResearch & News · Analysis
Loading stock research…